Bruyère workers rally in bid to force Ottawa hospital to reverse job cuts - Ottawa Citizen

Washington, D. C., September 30, 2026 (PAHO) – The Pan American Health Organization (PAHO), Regional Office for the Americas of the World Health Organization (WHO), and Canada’s Bruyère Health Research Institute (Bruyère Health RI) have signed a new five-year framework agreement to strengthen collaboration on disease elimination, health equity, innovation, and capacity-building across the Americas. The agreement will support PAHO’s Disease Elimination Initiative and other shared regional public health priorities by mobilizing expertise, strengthening partnerships, and promoting evidence-informed approaches to improve health outcomes, particularly among populations living in situations of vulnerability. Approved by PAHO Member States in 2019, the Disease Elimination Initiative seeks to eliminate more than 30 communicable diseases and related conditions in the Americas through integrated, sustainable, people-centered, and equity-focused approaches that strengthen health systems, address the social and environmental determinants of health, and promote multisectoral collaboration.

Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.